Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D, Tissue Ageing and Senescence Markers: Full Evidence Review

Previous related pageVitamin D, Tissue Ageing and Senescence Markers: Study SummaryNext related pageVitamin D, Immune Ageing and the Gap Between Markers and Function: Full Evidence Review
Study at a glance

What question did the studies ask?

Researchers asked whether vitamin D-related changes in cells lead to healthier ageing tissues. This review compares animal experiments, a small human skin test, blood-cell measurements and calculated biological-age scores. These studies measure different things. Senescent cells stop dividing for a long time but remain active.

What did the researchers find?

Some mouse experiments linked low active-vitamin-D signalling to bone changes. Deleting a gene that controls cell division or giving a separate drug improved selected features. Those interventions were not vitamin D3 treatment. Other experiments found worse lung injury with calcitriol, the active vitamin D hormone. The results do not establish the effects of ordinary oral vitamin D3 in people.

A small uncontrolled study found mixed changes in older adults’ skin immune responses to previously encountered viral material. A short randomized trial in older adults with low vitamin D levels found changes in selected blood-cell measurements. It did not show clear differences in blood inflammation measures or prove removal of senescent cells.

Human studies of DNA methylation clocks also gave mixed results. DNA carries genetic information. These clocks calculate age-related scores from chemical marks on DNA. The larger three-year trial did not show a clear vitamin D-alone effect on its four clocks. Positive findings for omega-3 or combined treatments cannot be assigned to vitamin D alone.

What does this mean?

These findings help investigate ageing biology. They do not establish that vitamin D rejuvenates human tissues, improves how tissues recover after stress or extends life.

Read the full article below ↓

Studies connect vitamin D-related signalling with some ageing-associated tissue changes, but they measure very different outcomes. Genetic mouse experiments, an uncontrolled human skin challenge, blood-cell markers and DNA methylation clocks cannot be treated as interchangeable demonstrations of rejuvenation. This review asks which tissue or human consequences were actually measured and how far they support a senescence-based explanation. For the shorter account, read Vitamin D, Tissue Ageing and Senescence Markers: Study Summary.

From a cell marker to a tissue consequence

Cellular senescence involves durable withdrawal from division together with context-dependent changes in cell behaviour. Markers such as p16 expression or beta-galactosidase staining can help investigate that state, but are not complete counts of senescent cells. Tissue ageing is broader still: structure, repair, immune responses and organ function can change through several interacting processes. The distinction is introduced in Vitamin D and Cellular Senescence and placed in a wider lifespan context in Vitamin D and Age-Related Decline.

This focused review compares primary studies rather than pooling their unlike outcomes. The question is not how many results are favourable. It is whether the design identifies the vitamin D-related exposure, measures a relevant tissue consequence and establishes senescence as a mediator. Removing a receptor, reducing active-hormone production, administering calcitriol, giving oral vitamin D3 and administering a senolytic drug are different interventions. Findings from one cannot silently supply the missing treatment comparison in another.

Resilience means preserving or recovering function under a challenge. A changed blood marker or calculated biological-age score may motivate that question without answering it. Similarly, the processes described in Vitamin D and Regeneration and Vitamin D and Tissue Repair need direct evidence at the relevant structural or functional level, rather than a favourable label applied to a molecular result. Tissue repair can involve matrix remodelling without requiring cell replacement in every case.

Skeletal models: regulatory evidence with partial genetic rescue

Xu and colleagues studied six-month-old male mice with one disrupted Cyp27b1 copy, alongside P27-deficient and combined genetic models. CYP27B1 helps produce calcitriol, the active vitamin D hormone. The experiments linked active-hormone insufficiency to altered skeletal and senescence-associated features and investigated a VDR: CDK2: P27 pathway. VDR is the vitamin D receptor; CDK2 and P27 regulate cell-cycle progression. Promoter-binding and reporter experiments supported CDK2 regulation, and protein experiments connected it with P27 degradation. [1]

Deleting P27 partially rescued skeletal features in the low-active-hormone model. This is useful causal evidence for a regulatory contribution, but the rescue was genetic, not a trial of vitamin D3. Global genetic changes can also alter systemic mineral physiology. Neither the number of changed markers nor improved bone architecture establishes that P27 deletion is a safe way to treat normal ageing. The broader skeletal setting is explained in Vitamin D and Bone. [1]

The human component used marrow stromal cultures from a small group of women undergoing osteoarthritis surgery. Early-passage cells were exposed to oxidative stress, and calcitriol responses were examined. This is not a test of older adults taking a supplement or of reversing long-term replicative senescence. Some assay denominators mix donor and technical replication, and small endpoint-specific samples limit precision. Early osteogenic markers also do not directly measure fracture resistance. Oxidative injury is a distinct context within Vitamin D and Oxidative Stress. [1]

A different drug tests a downstream senescence hypothesis

Yang and colleagues treated older Cyp27b1-heterozygous mice with navitoclax, also called ABT263, a drug used experimentally to target senescent cells. They reported improvements in selected bone and senescence-associated measurements. This tests whether acting downstream on the altered cell population can modify skeletal consequences in that genotype. It does not demonstrate that vitamin D supplementation produces the same effect. [2]

The main experiment lacked a wild-type-plus-drug arm, limiting assessment of genotype-specific benefit and wider effects. Changes in staining and bone measurements do not establish perfect drug selectivity across every tissue. The navitoclax and P27 papers share a broader research programme but contain distinct experiments; they are not independent laboratory replications of vitamin D efficacy. Together they strengthen a skeletal pathway question while leaving the nutritional treatment, safety and normal-ageing questions open. [2] [1]

Ovarian and lung findings limit a uniformly beneficial account

Chen and colleagues studied global Vdr-null mice and KGN cells, a tumour-derived granulosa-cell model. Ovarian structure, stress-associated measurements and reproductive-cycle features were altered. Supplementation with 7-dehydrocholesterol improved selected experimental features. That compound is a cholesterol-related precursor that can be used to make vitamin D3, not vitamin D3 itself. The experiment therefore does not establish restoration of fertility by vitamin D. [3]

Receptor-null animals also differ from an ordinary low-vitamin-D population, and global mineral disturbances complicate direct tissue attribution. Senescence-associated markers did not by themselves establish stable irreversible arrest in every relevant ovarian cell. Tumour-derived KGN cells further limit generalisation to normal ovarian ageing. The study supports investigating a receptor-related pathway, without proving a clinical treatment for ovarian insufficiency. [3]

Guijarro and colleagues found a contrary tissue direction in bleomycin-injured mice: calcitriol worsened selected fibrotic, DNA-damage and weight-loss outcomes. Their cell work showed increased senescence-associated features in injured A549 lung-cancer-derived cells, with different responses in other cell and injury settings. The inconsistent reported bleomycin dose prevents a secure precise dose comparison. These findings should remain visible, but do not establish that ordinary oral vitamin D3 harms human lungs or that senescence alone mediated the fibrosis. [4]

A human skin challenge: local function, small uncontrolled cohort

Chambers and colleagues studied 18 older white-European adults, with a median age of 69 years. Participants received oral cholecalciferol, or vitamin D3, at 6,400 international units daily for 14 weeks. They underwent a skin challenge with varicella-zoster antigen, which tests a local response to previously encountered viral material. This offers a functional observation beyond a blood marker, but it was not a randomized trial with a contemporaneous placebo group. [5]

Responses varied: seven participants did not improve, four improved mildly and seven improved by at least two score points. Some analyses involved fewer available samples. Overall challenge-related skin gene expression did not show a clear uniform change, and circulating inflammatory markers did not broadly improve. Subgroup and pathway findings must be interpreted within that mixed overall pattern. The local tissue setting is described in Vitamin D and Skin. [5]

Sayegh and colleagues later reanalysed this same cohort while examining inflammatory secretion by senescent fibroblasts. The publications are not two independent human confirmations. The cell intervention was calcitriol; the older-adult intervention was vitamin D3. An improvement in this skin test is not demonstrated prevention of shingles, vaccine efficacy, lifespan extension or a reduction in whole-body senescent-cell burden. [6] [5]

Randomized blood-cell markers are not clinical resilience

Rastgoo and colleagues randomized 88 older adults selected for vitamin D blood levels below 30 nanograms per millilitre to 1,000 or 5,000 international units of vitamin D3 daily, with or without 600 milligrams of N-acetylcysteine, for eight weeks. The formal correction changes erroneous 50,000-unit table labels to 5,000. That was the study eligibility threshold, not a universal clinical definition of deficiency. All groups received vitamin D3, so this was an active-regimen comparison rather than supplementation versus placebo. There was no N-acetylcysteine-only group. These doses describe the study and are not a recommended regimen. [7] [8]

The authors reported lower p16 and selected inflammatory-gene expression in the 5,000-unit groups compared with 1,000 units of vitamin D3 alone. These were measurements in peripheral blood mononuclear cells, a mixture of immune cells; they do not by themselves establish a clinical benefit or an advantage from adding N-acetylcysteine to 5,000 units alone. The beta-galactosidase result was green-stained pixel area, not the percentage of senescent cells. p21 expression did not show a significant between-group difference, and circulating interleukin-6, C-reactive protein and the neutrophil-to-lymphocyte ratio showed no significant between-group benefit. Internal disagreement in reported p16 numbers prevents a reliable precise effect-size claim. [7]

The randomized design supports a comparison of the tested regimens on these measured outcomes. It does not convert a marker into proof of senescent-cell clearance. The trial did not show improved resistance to infection, recovery after injury or long-term organ function. As explained in Vitamin D Status vs Vitamin D Effect, a measurable change in vitamin D status also does not automatically establish a particular tissue effect. [7]

DNA methylation clocks: the larger vitamin D-alone result was null

The DO-HEALTH analysis studied 777 Swiss participants from the larger randomized trial. Participants were randomized to different combinations of 2,000 international units of vitamin D3 daily versus its placebo, omega-3 versus its placebo, and an exercise-programme comparison over three years. They did not all receive the same three interventions. DNA methylation clocks use selected chemical marks on DNA to calculate age-related scores. They do not directly count senescent cells, measure tissue repair or observe how long a person will live. [9]

Vitamin D alone did not show a clear effect on the four assessed clock outcomes: PhenoAge, GrimAge, GrimAge2 and DunedinPACE. Their vitamin D-alone confidence intervals included no effect. Findings attributed to omega-3 or combined regimens cannot be reassigned to vitamin D alone. Even an apparent age difference expressed in months is a model-based translation of a score, not an observation that participants literally gained those months of life. [9]

The blood-based analysis came from a selected national subset, not every participant in the parent trial. Multiple clock and combination comparisons require caution. Its longer randomized exposure is informative, but neither a null clock nor a positive combination result answers every tissue-specific senescence question. It also does not test whether a response persists after vitamin D is withdrawn. [9]

Smaller and observational clock studies give a mixed picture

Vetter and colleagues analysed supplement use in the Berlin Aging Study II. Sixty-three self-selected users were matched with 63 non-users within a much larger follow-up population. Over approximately 7.4 years, selected clock associations favoured users while other clock results were null. The regimen was not adequately specified for a dose-effect conclusion, and some findings were sensitive to seasonal adjustment. Health behaviour and other residual confounding remain plausible explanations because supplement use was not randomized. [10]

A separate small randomized trial by Chen and colleagues reported mixed positive clock findings in overweight or obese African-American adults with suboptimal vitamin D status. The intervention used monthly dosing over 16 weeks, not daily tablets. The methylation analysis involved only a subset of the randomized population, with baseline differences and multiple comparisons. It supplies a useful qualitative counterpoint to DO-HEALTH, but not a secure estimate of lifespan, tissue regeneration or persistent gene regulation. [11]

These studies prevent the conclusion that all human clock findings are null. They also do not justify treating positive and null papers as equally strong votes. Sample selection, randomization, comparator, duration, assay and analytical choices differ. A clock change is several inferential steps away from a senescence-mediated physiological benefit. None of these studies establishes that blood-clock changes explain actual improvements in tissue resilience. [9] [10] [11]

Which conclusions survive the comparison?

Evidence settingWhat it contributesWhat remains unresolved
P27 genetic and navitoclax skeletal modelsRegulatory and downstream intervention evidence for selected bone phenotypesOrdinary vitamin D3 efficacy, safety and normal-human ageing
Ovarian receptor loss and precursor rescueA receptor-related stress and tissue questionVitamin D treatment and restored fertility
Bleomycin-injured lung modelsAn important contrary tissue directionOrdinary human oral-D3 effects and selective senescence mediation
Older-adult skin antigen challengeA small local functional observationRandomized clinical protection or whole-body cell clearance
Randomized blood-cell trialActive-regimen differences in selected markersClinical immune resilience or direct senescent-cell burden
Human methylation-clock studiesMixed surrogate findings, including a larger D-alone nullSlower tissue ageing, lifespan extension or lasting gene regulation

The tissue evidence is biologically informative but uneven. Some preclinical interventions strengthen a senescence-related causal pathway; others reveal injury-specific harm or leave systemic explanations open. Human studies provide selected local or surrogate observations, with no established general rejuvenation effect. The defensible conclusion is that vitamin D-related pathways can intersect with tissue ageing biology, while a clinically useful senescence-mediated benefit remains unproved by these studies.

Scientific sources

[1] Active vitamin D protects against osteoporosis by promoting VDR-dependent CDK2 transcription and P27 degradation. Xu F, Liu Q, Huang M, Wang J, Goltzman D, Gu B, Miao D. European journal of endocrinology. 2026;195(2):329-344. DOI 10.1093/ejendo/lvag152; PMID 42592858.

[2] The senolytic agent ABT263 ameliorates osteoporosis caused by active vitamin D insufficiency through selective clearance of senescent skeletal cells. Yang C, Qiao W, Xue Q, Goltzman D, Miao D, Dong Z. Journal of Orthopaedic Translation. 2024;49:107. DOI 10.1016/j.jot.2024.08.012; PMID 39430127; PMCID PMC11490840.

[3] Loss of vitamin D receptor induces premature ovarian insufficiency through compromising the 7-dehydrocholesterol-dependent anti-aging effects. Chen H, Wang Q, Zhang Y, Shangguan L, Zhu Z, Zhang H, Zou X, Geng Q, Wen Y, Wang D, Wang Y. Frontiers in cell and developmental biology. 2025;13:1545167. DOI 10.3389/fcell.2025.1545167; PMID 40276652; PMCID PMC12018433.

[4] Detrimental pro-senescence effects of vitamin D on lung fibrosis. Guijarro T, Magro-Lopez E, Manso J, Garcia-Martinez R, Fernandez-Aceñero MJ, Liste I, Zambrano A. Molecular medicine (Cambridge, Mass.). 2018;24(1):64. DOI 10.1186/s10020-018-0064-z; PMID 30567504; PMCID PMC6299997.

[5] Vitamin D3 replacement enhances antigen-specific immunity in older adults. Chambers ES, Vukmanovic-Stejic M, Turner CT, Shih BB, Trahair H, Pollara G, Tsaliki E, Rustin M, Freeman TC, Mabbott NA, Noursadeghi M, Martineau AR, Akbar AN. Immunotherapy Advances. 2021;1(1):ltaa008. DOI 10.1093/immadv/ltaa008; PMID 36284901; PMCID PMC9585673.

[6] Vitamin D3 inhibits p38 MAPK and senescence-associated inflammatory mediator secretion by senescent fibroblasts that impacts immune responses during ageing. Sayegh S, Fantecelle CH, Laphanuwat P, Subramanian P, Rustin MHA, Gomes DCO, Akbar AN, Chambers ES. Aging cell. 2024;23(4):e14093. DOI 10.1111/acel.14093; PMID 38287646; PMCID PMC11019144.

[7] Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial. Rastgoo S, Pourvali K, Raeissadat SA, Eslamian G, Zand H. Frontiers in immunology. 2025;16:1570441. DOI 10.3389/fimmu.2025.1570441; PMID 40421021; PMCID PMC12104082.

[8] Corrigendum: Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial Rastgoo S, Pourvali K, Raeissadat SA, Eslamian G, Zand H. Frontiers in Immunology. 2025;16:1627178. DOI 10.3389/fimmu.2025.1627178; PMID 40510343.

[9] Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial. Bischoff-Ferrari HA, Gängler S, Wieczorek M, Belsky DW, Ryan J, Kressig RW, Stähelin HB, Theiler R, Dawson-Hughes B, Rizzoli R, Vellas B, Rouch L, Guyonnet S, Egli A, Orav EJ, Willett W, Horvath S. Nature aging. 2025;5(3):376-385. DOI 10.1038/s43587-024-00793-y; PMID 39900648; PMCID PMC11922767.

[10] Vitamin D supplementation is associated with slower epigenetic aging. Vetter VM, Sommerer Y, Kalies CH, Spira D, Bertram L, Demuth I. GeroScience. 2022;44(3):1847-1859. DOI 10.1007/s11357-022-00581-9; PMID 35562603; PMCID PMC9213628.

[11] Effects of Vitamin D3 Supplementation on Epigenetic Aging in Overweight and Obese African Americans With Suboptimal Vitamin D Status: A Randomized Clinical Trial. Chen L, Dong Y, Bhagatwala J, Raed A, Huang Y, Zhu H. The journals of gerontology. Series A, Biological sciences and medical sciences. 2019;74(1):91-98. DOI 10.1093/gerona/gly223; PMID 30256915; PMCID PMC6612014.

Related reading

Original sources

Source

Active vitamin D protects against osteoporosis by promoting VDR-dependent CDK2 transcription and P27 degradation.

Published in Xu F, Liu Q, Huang M, Wang J, Goltzman D, Gu B, Miao D. European journal of endocrinology (2026).

Publication details

[1] Active vitamin D protects against osteoporosis by promoting VDR-dependent CDK2 transcription and P27 degradation. Xu F, Liu Q, Huang M, Wang J, Goltzman D, Gu B, Miao D. European journal of endocrinology. 2026;195(2):329-344. DOI 10.1093/ejendo/lvag152; PMID 42592858.

Read more →
Source

The senolytic agent ABT263 ameliorates osteoporosis caused by active vitamin D insufficiency through selective clearance of senescent skeletal cells.

Published in Yang C, Qiao W, Xue Q, Goltzman D, Miao D, Dong Z. Journal of Orthopaedic Translation (2024).

Publication details

[2] The senolytic agent ABT263 ameliorates osteoporosis caused by active vitamin D insufficiency through selective clearance of senescent skeletal cells. Yang C, Qiao W, Xue Q, Goltzman D, Miao D, Dong Z. Journal of Orthopaedic Translation. 2024;49:107. DOI 10.1016/j.jot.2024.08.012; PMID 39430127; PMCID PMC11490840.

Read more →
Source

Loss of vitamin D receptor induces premature ovarian insufficiency through compromising the 7-dehydrocholesterol-dependent anti-aging effects.

[3] Loss of vitamin D receptor induces premature ovarian insufficiency through compromising the 7-dehydrocholesterol-dependent anti-aging effects.

Publication details

[3] Loss of vitamin D receptor induces premature ovarian insufficiency through compromising the 7-dehydrocholesterol-dependent anti-aging effects. Chen H, Wang Q, Zhang Y, Shangguan L, Zhu Z, Zhang H, Zou X, Geng Q, Wen Y, Wang D, Wang Y. Frontiers in cell and developmental biology. 2025;13:1545167. DOI 10.3389/fcell.2025.1545167; PMID 40276652; PMCID PMC12018433.

Read more →
Source

Detrimental pro-senescence effects of vitamin D on lung fibrosis

The multiple biological effects of vitamin D and its novel activities on inflammation and redox homeostasis have raised high expectations on its use as a therapeutic agent for multiple fibrogenic conditions.

Publication details

[4] Detrimental pro-senescence effects of vitamin D on lung fibrosis. Guijarro T, Magro-Lopez E, Manso J, Garcia-Martinez R, Fernandez-Aceñero MJ, Liste I, Zambrano A. Molecular medicine (Cambridge, Mass.). 2018;24(1):64. DOI 10.1186/s10020-018-0064-z; PMID 30567504; PMCID PMC6299997.

Read more →
Source

Vitamin D3 replacement enhances antigen-specific immunity in older adults

We investigated the use of vitamin D3 replacement to enhance cutaneous antigen-specific immunity in older adults (≥65 years).

Publication details

[5] Vitamin D3 replacement enhances antigen-specific immunity in older adults. Chambers ES, Vukmanovic-Stejic M, Turner CT, Shih BB, Trahair H, Pollara G, Tsaliki E, Rustin M, Freeman TC, Mabbott NA, Noursadeghi M, Martineau AR, Akbar AN. Immunotherapy Advances. 2021;1(1):ltaa008. DOI 10.1093/immadv/ltaa008; PMID 36284901; PMCID PMC9585673.

Read more →
Source

Vitamin D3 inhibits p38 MAPK and senescence‐associated inflammatory mediator secretion by senescent fibroblasts that impacts immune responses during ageing

Vitamin D3 replacement in older insufficient adults significantly improves their antigen‐specific varicella zoster virus (VZV) cutaneous immunity.

Publication details

[6] Vitamin D3 inhibits p38 MAPK and senescence-associated inflammatory mediator secretion by senescent fibroblasts that impacts immune responses during ageing. Sayegh S, Fantecelle CH, Laphanuwat P, Subramanian P, Rustin MHA, Gomes DCO, Akbar AN, Chambers ES. Aging cell. 2024;23(4):e14093. DOI 10.1111/acel.14093; PMID 38287646; PMCID PMC11019144.

Read more →
Source

Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial.

Published in Rastgoo S, Pourvali K, Raeissadat SA, Eslamian G, Zand H. Frontiers in immunology (2025).

Publication details

[7] Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial. Rastgoo S, Pourvali K, Raeissadat SA, Eslamian G, Zand H. Frontiers in immunology. 2025;16:1570441. DOI 10.3389/fimmu.2025.1570441; PMID 40421021; PMCID PMC12104082.

Read more →
Source

Corrigendum: Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial

Published in Rastgoo S, Pourvali K, Raeissadat SA, Eslamian G, Zand H. Frontiers in Immunology (2025).

Publication details

[8] Corrigendum: Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial Rastgoo S, Pourvali K, Raeissadat SA, Eslamian G, Zand H. Frontiers in Immunology. 2025;16:1627178. DOI 10.3389/fimmu.2025.1627178; PMID 40510343.

Read more →
Source

Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial.

[9] Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial.

Publication details

[9] Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial. Bischoff-Ferrari HA, Gängler S, Wieczorek M, Belsky DW, Ryan J, Kressig RW, Stähelin HB, Theiler R, Dawson-Hughes B, Rizzoli R, Vellas B, Rouch L, Guyonnet S, Egli A, Orav EJ, Willett W, Horvath S. Nature aging. 2025;5(3):376-385. DOI 10.1038/s43587-024-00793-y; PMID 39900648; PMCID PMC11922767.

Read more →
Source

Vitamin D supplementation is associated with slower epigenetic aging

We previously reported on an association between vitamin D deficiency and higher 7-CpG DNAmAA in participants of the Berlin Aging Study II (BASE-II).

Publication details

[10] Vitamin D supplementation is associated with slower epigenetic aging. Vetter VM, Sommerer Y, Kalies CH, Spira D, Bertram L, Demuth I. GeroScience. 2022;44(3):1847-1859. DOI 10.1007/s11357-022-00581-9; PMID 35562603; PMCID PMC9213628.

Read more →
Source

Effects of Vitamin D3 Supplementation on Epigenetic Aging in Overweight and Obese African Americans With Suboptimal Vitamin D Status: A Randomized Clinical Trial.

[11] Effects of Vitamin D3 Supplementation on Epigenetic Aging in Overweight and Obese African Americans With Suboptimal Vitamin D Status: A Randomized Clinical Trial.

Publication details

[11] Effects of Vitamin D3 Supplementation on Epigenetic Aging in Overweight and Obese African Americans With Suboptimal Vitamin D Status: A Randomized Clinical Trial. Chen L, Dong Y, Bhagatwala J, Raed A, Huang Y, Zhu H. The journals of gerontology. Series A, Biological sciences and medical sciences. 2019;74(1):91-98. DOI 10.1093/gerona/gly223; PMID 30256915; PMCID PMC6612014.

Read more →